Half-Year 2022 Financial and Clinical Trials Update
gRED oncology development programs
Roche
Molecule
Indication
Phase
# of patients
Status
CT Identifier
Oncology
KRAS G12C (RG6330)
cevostamab
(anti-FcRH5 x CD3; RG6160)
runimotamab
(HER2 x CD3, RG6194)
NME (RG6286)
Metastatic solid tumors with KRAS
G12C mutation
270
FPI Q3 2020
NCT04449874
FPI Q3 2017
R/R multiple myeloma
300
NCT03275103
Data presented at ASH 2020, ASH 2021
Metastatic HER2-expressing cancers
440
FPI Q2 2018
NCT03448042
Locally advanced or metastatic
67
FPI Q3 2020
NCT04468607
colorectal cancer
Solid tumors
1/11
250
FPI Q1 2020
IL15/IL15Ra-Fc (RG6323)1
R/R multiple myeloma
|
60
FPI Q2 2022
NCT04250155
NCT05243342
FPI Q4 2017
Solid tumors
la/llb
271
autogene cevumeran
(Individualized Neoantigen-Specific
Therapy (iNeST); RG6180)²
1L advanced melanoma
||
=
132
FPI Q1 2019
Data presented at AACR 2020
Recruitment completed Q1 2022
NCT03289962
NCT03815058
(IMcode001)
NCT04252339
SHP2i (RG6344)
Solid tumors
la
~50
FPI Q1 2020
belvarafenib (RG6185)³
nRASmt CPI-experienced melanoma
lb
83
FPI Q2 2021
NCT04835805
ISRCTN92655
NME (RG6392)
Oncology
60
FPI Q4 2021
801
Partner: 1Xencor, 2BioNTech, ³Hanmi
157View entire presentation